Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea I was impatient because of all the gains in the weed stocks. Wanted to use the money somewhere else. But that is what I'm going to do from now on. Take out my original investments plus a bit more and let the rest ride. ZLCS might still be good of they do something with z944. It is kinda like their hail marry.
Don't be mad. That's an awesome gain..learn from it though. You could have sold enough shares to cover your initial investment and sat on "free shares".
I'm kinda mad at myself. I bought in at .99 and sold at 1.38.
here it goes!
it held up, now for the pressure to build for end of day direction
1.70..watch for $2 break end of day
Ragin Cajun.Slow and steady wins the race.The gap will be filled.IMO.
When it breaks 1.79 resistance Massive Explosion to the 3.00's follows! $$$$$$$$$$
Broke out above 1.43 here we gooo back above 3.00 $$$$$$$$$$$$$
Back All In @ 1.35 See you at 5.00 at least on the the way back to 8.00 Weeeeee! $$$$$$$$$$$$$$$$
Wow! This is a surprise, wonder what's up here.
Nice open today with Zalcus Hopefully we can maintain this today!!!
I think I was wrong. Seems there is no news coming. I know they are putting everything into z944. Z160 took this from 5 to 1. I don't think it will get back up there but if they come out with some z944 news we should get closer to the 2 dollar range. Since the fall seems 1.30 is the resistance.
Maybe this explains the high vol yesterday. very nice with those tight bollies getting pierced
Nice bump today. I think we are suppsod to have some phase 2 results on Z944 this month.
Just took a position. Liking the chart
I took the 6% and got out... Not bad for two days. I may be back though
+6% today ... I hope so!
$ZLCS The best outcome for Zalicus is to partner with big pharma for Z944.
Bullish Stocks Analysis: Zalicus Inc, Camtek Ltd, JPMorgan Chase & Co, Nevada Gold Corp
Nov 27, 2013 (ACCESSWIRE via COMTEX) -- New York, November 27, 2013
Moving notably higher on the session are shares of beaten down pain management company Zalicus Inc ZLCS -2.42% . Volume is already more than double the 10-day average in the name.Still, the shares are ~75% below where they traded before news hit that Z160 did not meet its primary endpoint in two Phase 2 trials. The company is now pinning its hopes on Z944.Here's SA contributor Jason Napodano: "I spoke with management. Talked about a number of reasons why Z944 is different from Z160. Will share soon."
http://www.wired.com/gadgetlab/2012/08/apple-amazon-mat-honan-hacking/
$ZLCS Zalicus Inc. and Hydra Biosciences, Inc announced that they have entered into a collaboration to advance development of Zalicus’ preclinical ion channel modulator product candidates for the treatment of pain. This collaboration brings together the Zalicus portfolio of, preclinical ion channel product candidates, representing multiple calcium and sodium channel modulators, with Hydra’s in ion channel discovery and preclinical drug development. The goal of the collaboration is to advance ion channel drug candidates into clinical development for the treatment of pain.
$ZLCS Zalicus Inc announced that it has been granted a patent by the U.S. Patent and Trademark office (USPTO) covering its product candidate Z944. United States patent number 8,377,968 entitled N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers provides broad coverage for Z944 including compositions of matter and certain therapeutic methods of use through April 2029.
$ZLCS Zalicus Inc. Discovers Multi-Target Mechanism For Treatment of Multiple Myeloma
$ZLCS Z944 P1b showed reduced pain. Big pharma will be interested. Partnership or buyout is the way to go.
Go back to $0.88 (second leg?)
I bought all the shares at $0.88 ~ $0.89 and sold all at 50% quick gain. Thanks for those brave buyers who bought mine!
I respectfully disagree as the facts show otherwise.
They still have income, (not much). There is a GREAT opportunity to swing trade it. That is what is happening. VERY liquid, and a TON of money to be made Long or Short.. GL
To the non-traders out there...
This stock is DEAD. Failed trials are the
death knell for them. There is nothing
left in the pipeline that is significant
If you are holding this stock same time next
year you will be holding nothing but a write-off
If you got destroyed on the last plunge,
sell now for this year's write off
Don't be fooled again, this stock has NO potential whatsoever
ZLCS-Insane Trading going on.. 1.33...
That outperform rating is old and was under the assumption that they wouldn't have been spanked by the FDA
Does today look like the start of it?
IMO, $0.75 will be tested very soon! $0.88 will be broken tomorrow!
Another new 52-week low $0.88 was created so far! What a pos scam!
Looks like they want to take this down a bit more today. I'll check back in a day or 2.
$ZLCS Oppenheimer rated Zalicus market perform, with PT $12.
http://www.analystratings.net/r/249940
$ZLCS Z944 was proved to have pain control property in human trial. http://finance.yahoo.com/news/zalicus-announces-positive-results-z944-123000189.html
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2191
|
Created
|
08/12/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=ZLCS
http://www.form4oracle.com/company?cik=0001135906&ticker=crxx
Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinson's disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. on September 9, 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |